Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
10.4093/dmj.2021.0158
Author:
Kyuho KIM
1
;
Sung Hee CHOI
Author Information
1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea